234 related articles for article (PubMed ID: 36411623)
1. The pathogenesis of anti-signal recognition particle necrotizing myopathy: A Review.
Qiu R; Wang Z; Wei X; Sui H; Jiang Z; Yu XF
Biomed Pharmacother; 2022 Dec; 156():113936. PubMed ID: 36411623
[TBL] [Abstract][Full Text] [Related]
2. Immune-Mediated Necrotizing Myopathy.
Pinal-Fernandez I; Casal-Dominguez M; Mammen AL
Curr Rheumatol Rep; 2018 Mar; 20(4):21. PubMed ID: 29582188
[TBL] [Abstract][Full Text] [Related]
3. Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge.
Merlonghi G; Antonini G; Garibaldi M
Autoimmun Rev; 2022 Feb; 21(2):102993. PubMed ID: 34798316
[TBL] [Abstract][Full Text] [Related]
4. Immune-mediated necrotizing myopathy: clinical features and pathogenesis.
Allenbach Y; Benveniste O; Stenzel W; Boyer O
Nat Rev Rheumatol; 2020 Dec; 16(12):689-701. PubMed ID: 33093664
[TBL] [Abstract][Full Text] [Related]
5. Perivascular and endomysial macrophages expressing VEGF and CXCL12 promote angiogenesis in anti-HMGCR immune-mediated necrotizing myopathy.
Lia A; Annese T; Fornaro M; Giannini M; D'Abbicco D; Errede M; Lorusso L; Amati A; Tampoia M; Trojano M; Virgintino D; Ribatti D; Serlenga L; Iannone F; Girolamo F
Rheumatology (Oxford); 2022 Aug; 61(8):3448-3460. PubMed ID: 34864921
[TBL] [Abstract][Full Text] [Related]
6. Anti-SRP immune-mediated necrotizing myopathy: A critical review of current concepts.
Ma X; Bu BT
Front Immunol; 2022; 13():1019972. PubMed ID: 36311711
[TBL] [Abstract][Full Text] [Related]
7. Peculiar clinicopathological features of immune-mediated necrotizing myopathies.
Allenbach Y; Benveniste O
Curr Opin Rheumatol; 2018 Nov; 30(6):655-663. PubMed ID: 30239349
[TBL] [Abstract][Full Text] [Related]
8. Anti-signal recognition particle positive necrotizing myopathy-sjogren's syndrome overlap syndrome: a descriptive study on clinical and myopathology features.
Xu L; Yang MG; Hu L; Gao H; Ji S
BMC Musculoskelet Disord; 2023 Mar; 24(1):219. PubMed ID: 36959614
[TBL] [Abstract][Full Text] [Related]
9. [Clinical and pathological characteristics of immune mediated necrotizing myopathy].
Yang HX; Tian XL; Jiang W; Li WL; Liu QY; Peng QL; Wang GC; Lu X
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 51(6):989-995. PubMed ID: 31848492
[TBL] [Abstract][Full Text] [Related]
10. Immune-Mediated Necrotizing Myopathy (IMNM): A Story of Antibodies.
Julien S; Challier I; Malleter M; Jouen F; Drouot L; Boyer O
Antibodies (Basel); 2024 Feb; 13(1):. PubMed ID: 38390873
[TBL] [Abstract][Full Text] [Related]
11. Rheumatoid Arthritis Associated With Anti-Signal Recognition Particle Immune-Mediated Necrotizing Myopathy: A Case Report.
Belkhribchia MR; Lobrinus JA; Semlil L; Chauveau N; Ajrinija A; Egervari K; Ennhaili ZE
J Investig Med High Impact Case Rep; 2024; 12():23247096241231646. PubMed ID: 38353222
[TBL] [Abstract][Full Text] [Related]
12. Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies.
Ladislau L; Arouche-Delaperche L; Allenbach Y; Benveniste O
Curr Rheumatol Rep; 2018 Aug; 20(9):56. PubMed ID: 30074107
[TBL] [Abstract][Full Text] [Related]
13. [Retrospective study on clinical manifestation, thigh MRI and electrophysiology characteristics of immune-mediated necrotizing myopathy].
Qiao LY; Shi Q; Lin MY; Liu J; Chen ZJ; Pu C
Zhonghua Nei Ke Za Zhi; 2022 Oct; 61(10):1144-1151. PubMed ID: 36207969
[No Abstract] [Full Text] [Related]
14. Belimumab for Immune-Mediated Necrotizing Myopathy Associated With Anti-SRP Antibodies: A Case Report and Retrospective Review of Patients Treated With Anti-B-Cell Therapy in a Single Center and Literature.
Cui BB; Tian YR; Ma XY; Yin G; Xie Q
Front Immunol; 2021; 12():777502. PubMed ID: 34925350
[TBL] [Abstract][Full Text] [Related]
15. Pathologic Features of Anti-Ku Myositis.
Oyama M; Holzer MT; Ohnuki Y; Saito Y; Nishimori Y; Suzuki S; Shiina T; Leonard-Louis S; Benveniste O; Schneider U; Stenzel W; Nishino I; Suzuki S; Uruha A
Neurology; 2024 Apr; 102(8):e209268. PubMed ID: 38547417
[TBL] [Abstract][Full Text] [Related]
16. Immune Mediated Necrotizing Myopathy: Where do we Stand?
Mohammed AGA; Gcelu A; Moosajee F; Botha S; Kalla AA
Curr Rheumatol Rev; 2019; 15(1):23-26. PubMed ID: 29623846
[TBL] [Abstract][Full Text] [Related]
17. Paraneoplastic Anti-3-hydroxy-3-methylglutary-coenzyme A Reductase Antibody-positive Immune-mediated Necrotizing Myopathy in a Patient with Uterine Cancer.
Mizuma A; Kouchi M; Netsu S; Yutani S; Kitao R; Suzuki S; Murata K; Nagata E; Takizawa S
Intern Med; 2017; 56(14):1915-1918. PubMed ID: 28717093
[TBL] [Abstract][Full Text] [Related]
18. Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy.
Anquetil C; Boyer O; Wesner N; Benveniste O; Allenbach Y
Autoimmun Rev; 2019 Mar; 18(3):223-230. PubMed ID: 30639649
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptors and IL-7 as potential biomarkers for immune-mediated necrotizing myopathies.
Cappelletti C; Brugnoni R; Bonanno S; Andreetta F; Salerno F; Canioni E; Vattemi GNA; Tonin P; Mantegazza R; Maggi L
Eur J Immunol; 2023 Nov; 53(11):e2250326. PubMed ID: 37562045
[TBL] [Abstract][Full Text] [Related]
20. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy.
Watanabe Y; Uruha A; Suzuki S; Nakahara J; Hamanaka K; Takayama K; Suzuki N; Nishino I
J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1038-44. PubMed ID: 27147697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
